Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY24 of ₹1,177.00 Crores down from ₹1,939.00 Crore year on year, a fall of 14.38%.
Total Expenses for Q4FY24 of ₹1,026.00 Crores up from ₹929.00 Crores year on year, a rise of 10.44%.
Consolidated Net Profit of ₹115.00 Crores up 49.35% from ₹77.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹2.33, up 31.64% from ₹1.77 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.